mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

mRNA technologies have recently proven clinical efficacy against coronavirus disease 2019 and are among the most promising technologies to address the current pandemic. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle-encapsulated mRNA vaccine that encodes full-...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauch, Susanne, Roth, Nicole, Schwendt, Kim, Fotin-Mleczek, Mariola, Mueller, Stefan O., Petsch, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052455/
https://www.ncbi.nlm.nih.gov/pubmed/33863911
http://dx.doi.org/10.1038/s41541-021-00311-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052455/
https://www.ncbi.nlm.nih.gov/pubmed/33863911
http://dx.doi.org/10.1038/s41541-021-00311-w

Ejemplares similares